Stamford Health Adopts HIFU Therapy for Pain and Cancer

The hospital now offers noninvasive ultrasound procedures to treat chronic lower back pain and prostate cancer.

Updated on Oct. 28, 2026 in Cancer

Stamford Health Adopts HIFU Therapy for Pain and Cancer

Live Poll

Do you trust new medical technologies to improve long-term treatment outcomes for chronic pain?

As of August 2026, Stamford Health has implemented the Neurolyser XR high-intensity focused ultrasound system for chronic lower back pain and FocalOne therapy for prostate cancer. These noninvasive procedures provide patients in Fairfield County with alternatives to traditional surgeries and needle-based treatments.

Why it matters

HIFU therapy reduces patient risks like bleeding and complications associated with traditional needle-based radiofrequency ablation or invasive cancer surgeries. By offering these precise ultrasound treatments, the hospital aims to minimize side effects and improve recovery times for local residents.

The HIFU procedure is approximately 30% faster than traditional radiofrequency ablation, which typically relies on heated needles to target nerves. Arthritis-related lumbar facet joint pain, which this system treats, accounts for 15% to 45% of total back pain cases.

The players

Stamford Health

A health system serving Fairfield County that is the only facility in the area offering HIFU focal therapy for prostate cancer.

Food and Drug Administration

The federal agency responsible for evaluating and authorizing the use of new medical devices like the Neurolyser XR system.

The details

The Neurolyser XR system creates thermal lesions to treat back pain without the need for anesthesia or needles. Similarly, the FocalOne HIFU therapy utilizes a rectal probe to deliver ultrasound waves that heat and destroy prostate cancer cells.

The FDA approved the Neurolyser XR system earlier in 2026.
Stamford Health launched the HIFU procedure during the last few months.
A patient was treated with HIFU for back pain in the fall of 2026.

Health Landscape

The adoption of the Neurolyser XR system follows the regulatory path established by the FDA's 2026 device approval protocols. This move positions the hospital at the forefront of the shift toward noninvasive, thermal-based interventions in regional oncology and pain management.

Patients may experience shorter procedure times and avoid the risks of bleeding and general anesthesia associated with traditional surgeries. These treatments offer new options for managing chronic back pain and localized prostate cancer within the local community.

The takeaway

Advancements in ultrasound technology are making common medical interventions faster and less invasive for many patients. Those suffering from chronic back pain or prostate issues should consult their healthcare provider to see if focal therapy is appropriate for their specific condition.